This article was written by Follow My name is Andres Veurink and I have been in the financial markets for over a decade at this point, spending the majority of that in
Deals and Financings Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for its next-gen PARP1 inhibitor to Germany’s Merck KGaA (OTCPK:MKGAF) for a $170 million
TransUnion (NYSE:) CIBIL’s Credit Market Indicator (CMI) for Q2 2023 has revealed a rise in balance-level serious delinquencies across all product categories, with the